USH

USH Therapeutics is a biotechnology company dedicated to developing transformative gene-based therapies for Usher syndrome, a leading cause of combined deafness and blindness. The company focuses on addressing the genetic mutations in the USH2A gene, which are responsible for the most common form of the condition. By utilizing advanced genetic medicine approaches, USH Therapeutics aims to preserve and restore vision and hearing in affected patients. The company's research is centered on overcoming the challenges of delivering large genes to the retina and inner ear. USH Therapeutics is positioned at the forefront of precision medicine for rare sensory disorders.